Skip to main content

Table 1 Sequences of study treatment administrations

From: Add-on histamine receptor-3 antagonist for allergic rhinitis: a double blind randomized crossover trial using the environmental exposure unit

Sequence

Number of participants

Study period

1

2

3

4

1

4

B

D

B

C

2

4

B

B

C

D

3

4

C

B

D

B

4

4

D

C

B

B

5

12

A

C

A

C

6

12

C

A

C

A

7

12

A

C

C

A

8

12

C

A

A

C

  1. A: PF-03654764 capsule (5 mg) + fexofenadine capsule (60 mg) + placebo capsule.
  2. B: PF-03654764 capsule (5 mg) + placebo capsule + placebo capsule.
  3. C: placebo capsule + placebo capsule + fexofenadine (60 mg)/pseudoephedrine (120 mg) capsule.
  4. D: placebo capsule + placebo capsule + placebo capsule.